Boothbay Fund Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Boothbay Fund Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-786,800	Closed	-$13.1M	–	1417
2025 Q1	$13.1M	Buy	+786,800	New	+$14.3M	0.34%	45
2024 Q2	–	Sell	-212,100	Closed	-$3.92M	–	1479
2024 Q1	$3.92M	Buy	+212,100	New	+$5.25M	0.08%	303
2023 Q4	–	Sell	-134,400	Closed	-$2.8M	–	1614
2023 Q3	$2.8M	Buy	+134,400	New	+$3.65M	0.07%	382
2020 Q2	–	Sell	-206	Closed	-$870K	–	939
2020 Q1	$870K	Buy	+206	New	+$8.49K	0.07%	332

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Boothbay Fund Management's ACAD Position: Q2 2026 in Review

Boothbay Fund Management opened a new position in Acadia Pharmaceuticals (ACAD) in Q2 2026: 17,183 shares worth $435K. The stake represents 0.01% of the portfolio and ranks #1584 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in ACAD as recently as Q2 2025.

Boothbay Fund Management first reported a position in ACAD in Q3 2018 and has held it in 12 quarters since. The position peaked at $951K in Q3 2022. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Boothbay Fund Management held 17,183 shares of Acadia Pharmaceuticals worth $435K as of Q2 2026.
Acadia Pharmaceuticals was a new Boothbay Fund Management position in Q2 2026.
Acadia Pharmaceuticals made up 0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #1584 holding.
Boothbay Fund Management first reported a position in Acadia Pharmaceuticals in Q3 2018 and has held it in 12 quarters since.
Boothbay Fund Management's Acadia Pharmaceuticals position peaked at $951K in Q3 2022.
353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.